Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
about
Low serum C4 concentrations: an inherited predisposition to insulin dependent diabetes?Cryoglobulins, circulating immune complexes, and complement activation in cerebral malaria.Drug induced impairment of polymorphonuclear cell bactericidal ability in rheumatoid arthritis.Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies.Complement activation and HLA-B27Activation of the alternative complement pathway: clinical application of a new technique to measure fragment Ba.C3 degradation products (C3d) in normal pregnancy.Links between complement abnormalities and systemic lupus erythematosus.Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.Complement and systemic lupus erythematosus.Complement activation profiles in disease.Complement activation during cardiopulmonary bypass: quantitative study of effects of methylprednisolone and pulsatile flow.Mesenchymal stem cells inhibit complement activation by secreting factor H.Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the diseaseC3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.A quantitative lateral flow assay to detect complement activation in bloodComplement Activation in Patients with Focal Segmental Glomerulosclerosis.New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus.Immune complexes in human diseases: a reviewBinding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytesImmunonephelometric quantitation of complement split product (C3d) plasma levels in rheumatic disease.Clinical application of a new nephelometric technique to measure complement activationDecreased heat-labile opsonic activity and complement levels associated with evidence of C3 breakdown products in infected pleural effusions.Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.Soluble immune complexes in human disease.The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.Pathways to complement activation during cardiopulmonary bypass.Immune complex nephritis complicating miliary tuberculosis.Clinical applications of immunofixation: detection and quantitation of complement activation.Pulmonary dysfunction is common during a cytomegalovirus infection after renal transplantation even in asymptomatic patients. Possible relationship with complement activation.Immune complexes and complement hypercatabolism in patients with leprosy.SLE and Serum Complement: Causative, Concomitant or Coincidental?Sequential studies of complement activation in systemic lupus erythematosus.Association between E-selectin expression and histopathological modification of glomerular lesions by non-nephritogenic IgM antibodies in experimental lupus nephritis.The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.Synthesis and chemoinformatics analysis of N-aryl-β-alanine derivatives
P2860
Q24675648-7F200B0C-DECD-43D0-B34D-A8065DD12B92Q33483605-338F18F6-30A0-4178-8EF1-5011DD636142Q33557178-BA2787A5-5B53-4BA5-A231-202E86A56160Q33557184-A7C9A710-5F2A-47C1-9B34-E86154A8F979Q33560757-73CE63BC-918F-43B4-9179-B8EC97F46D09Q33838295-BDBDBBAD-25EE-44F9-9701-2D5F54FE7405Q33838393-A05D926A-0608-4E0A-9E29-7952DF5E99FFQ33867927-A9342A53-9589-41D8-9A80-C546071E9C04Q34558907-F32B5EFD-5578-4F28-8A6B-64F4C8E6639DQ34731255-E4BC2349-B7C8-45A7-AE68-DEBED7986D83Q34860585-C18C5C32-2F70-4389-8EF5-DA2B2939D894Q34996368-E30E4EAE-6C2E-43E8-A9EC-01BEB2415F5CQ35106559-788A75A1-7BF5-45AB-8FB7-0ED8497E57D2Q35200906-383F5C0B-0330-4E88-846B-7E01941E907FQ35201919-ECA08DC8-6030-4823-B99C-A6C7CE3D42E7Q35498749-9B71AF10-9E5E-4890-9B74-41D754DE6884Q35763276-B820677F-E812-4F4C-8C55-57D49C1885BCQ35824467-65BE4EA7-0534-46D9-8E50-4CF555F7425EQ35863255-E5B9C064-2BB4-4494-9B08-098E3AD03FE8Q36359022-B8543196-92CB-47C8-B9D9-161763352CABQ36487900-A29A4794-5E8B-4643-A7EF-9D67B5AD91B1Q36616293-9F31B972-5F55-4F13-81D9-5B9E1A24B014Q37035971-90BD3D36-67BB-4B17-9237-E4173824D8B7Q37044336-F416348C-0D55-4BAE-94B8-D918CC18E990Q38724499-97556895-56DE-4D5F-B0C3-B6FAAAAD3E3FQ39537318-B416155D-95AB-429D-B84D-7F9CDCECA72FQ40217274-DAD60D17-7C67-4FE5-97E5-044EC9E41473Q41139397-ADEDD067-9306-471B-A76D-7E8A623C6CA5Q41869025-8F328A67-7E9E-4566-8244-2AB0CE777B12Q42041225-DA0F977F-86D5-459D-8846-B147EC0B7372Q42740292-DCC8E57C-3368-4322-99AD-E697FB51F610Q43559427-7CD91D77-79DA-4719-B68C-2F163546245AQ45348139-C058BD8E-5E60-4960-9F8A-8E55B5432EBEQ47139886-5CEDE38E-043B-484B-8624-AD1EC8148B5AQ54073818-8C09846F-1090-4761-BD6A-8ECD66B7D7FAQ54392828-D41A5FB5-2700-4AAF-95DD-91B11F73C6B6Q55147541-3235326A-2DE7-4365-9752-E4236C4608DCQ56973813-F47D885E-2156-4380-BFA9-D059B07377E7
P2860
Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
description
1975 nî lūn-bûn
@nan
1975 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
Complement breakdown products ...... e or other glomerulonephritis.
@ast
Complement breakdown products ...... e or other glomerulonephritis.
@en
type
label
Complement breakdown products ...... e or other glomerulonephritis.
@ast
Complement breakdown products ...... e or other glomerulonephritis.
@en
prefLabel
Complement breakdown products ...... e or other glomerulonephritis.
@ast
Complement breakdown products ...... e or other glomerulonephritis.
@en
P2093
P2860
P356
P1476
Complement breakdown products ...... e or other glomerulonephritis.
@en
P2093
Lambert PH
Miescher PA
P2860
P304
P356
10.1172/JCI108065
P407
P577
1975-07-01T00:00:00Z